What We're Reading: Page 290
Industry reads hand-picked by our editors
Oct 09, 2017
-
The New York Times
As cancer tears through Africa, drug makers draw up a battle plan
-
Bloomberg
Big pharma gets boost as China speeds up new drug approvals
-
BBC
Thalidomide campaigners in talks with German government
-
Business Insider
Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine
Oct 06, 2017
Oct 05, 2017
-
Nikkei Asian Review
Novartis wants Japan to link drug price to patient outcomes
-
Bloomberg Gadfly
Evidence of biotech froth continues to mount
-
Vox
The 2017 Nobel Prize in chemistry, explained in 500 words
-
Financial Times
In-house lawyers are the new pathfinders
Oct 04, 2017
-
Medical Marketing & Media
7 professional paths of 7 pharma execs
-
Bloomberg
Allergan patent deal may hurt competition, lawmakers say
-
Xconomy
Palleon lands $46M to develop new type of checkpoint cancer drug
Oct 03, 2017
Oct 02, 2017
-
The Wall Street Journal
How a failed Alzheimer’s drug stung some large hedge funds
-
Forbes
CRISPR-focused biotech co-founded by Forbes Under 30 alumnus raises $76 million
-
The Guardian
Bad medicine: the toxic fakes at the heart of an international criminal racket
-
The New York Times
The wrong pill can play with your mind
Previous
